Superior Planning, LLC’s Bicara Therapeutics BCAX Stock Holding History

Superior Planning, LLC’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$801	Buy	+43	New	+$1.08K	﹤0.01%	1797

Other funds holding BCAX

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Superior Planning, LLC's BCAX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Bicara Therapeutics (BCAX) in Q3 2026: 43 shares worth $801. The stake represents ﹤0.01% of the portfolio and ranks #1797 among its holdings.

86 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

Superior Planning, LLC held 43 shares of Bicara Therapeutics worth $801 as of Q3 2026.
Bicara Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Bicara Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1797 holding.
86 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.